Aytu BioPharma Inc (NASDAQ:AYTU) Shares Fall on Q4 Revenue and EPS Miss

Aytu BioPharma Inc (NASDAQ:AYTU) Reports Q4 Fiscal 2025 Results; Shares Decline on Revenue and EPS Miss

Aytu BioPharma Inc has released its financial results for the fourth quarter and full fiscal year ended June 30, 2025. The company's performance fell short of analyst expectations on key metrics, leading to a significant negative reaction in after-hours trading.

Earnings and Revenue Performance

The company's fourth-quarter results did not meet Wall Street forecasts. Aytu reported a net loss for the quarter of $19.8 million, which contributed to a substantial miss on earnings per share.

• Q4 2025 Reported Revenue: $15.1 million
• Q4 2025 Analyst Revenue Estimate: $18.3 million
• Q4 2025 Reported Non-GAAP EPS: -$0.26
• Q4 2025 Analyst EPS Estimate: -$0.037

The revenue shortfall of approximately $3.2 million, coupled with a much larger-than-expected loss per share, appears to be the primary driver behind the negative investor sentiment. For the full fiscal year 2025, the company reported net revenue of $66.4 million, a slight increase from the $65.2 million reported in the prior year.

Market Reaction

Following the earnings release, shares of Aytu BioPharma experienced a sharp decline in after-market trading. The stock was down approximately 13.5%, reflecting investor disappointment with the quarterly figures. This price action suggests the market was anticipating results closer to or above analyst estimates.

Operational Highlights and Strategic Focus

Despite the earnings miss, the company's press release highlighted several operational achievements and a clear strategic direction. Aytu reported its ninth consecutive quarter of positive adjusted EBITDA, which was $2.0 million for both Q4 fiscal 2025 and the year-ago quarter. Full-year adjusted EBITDA was $9.2 million.

A significant portion of the announcement focused on the upcoming commercial launch of EXXUA™ (gepirone) extended-release tablets, a treatment for Major Depressive Disorder (MDD). The company confirmed that the launch remains on track for the fourth calendar quarter of 2025. Management characterized EXXUA as a "major growth catalyst," emphasizing its potential in the over $22 billion U.S. prescription MDD market. The company believes EXXUA is a novel, first-in-class oral selective serotonin 5HT1a receptor agonist.

Other key financial details from the report include:

• Cash Position: The company ended the quarter with a cash balance of $31.0 million, an increase from $18.2 million at the end of the previous quarter.
• Portfolio Performance: Revenue from the ADHD product portfolio was relatively stable year-over-year at $57.6 million, while the Pediatric portfolio showed growth, increasing to $8.8 million from $7.3 million in fiscal 2024.
• Net Loss: The full-year net loss improved to $13.6 million, compared to a net loss of $15.8 million in fiscal 2024.

Looking Ahead

The press release did not provide specific quantitative financial guidance for the coming fiscal year. Instead, management commentary focused on the transformational potential of the EXXUA launch. Josh Disbrow, Chief Executive Officer, stated the company expects to "exit fiscal 2026 on a trajectory that positions Aytu as one of the fastest growing CNS-focused companies in the industry."

Analyst estimates for the upcoming year project a challenging path, with an estimated EPS of -$0.87 on sales of $71.9 million for the full 2026 fiscal year. The success of the EXXUA launch will be critical in determining whether Aytu can outperform these current expectations.

For a detailed breakdown of historical earnings and future analyst estimates, review the AYTU earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security.